Placeholder Banner

BIO Welcomes Senate Agreement on GMO Labeling

June 23, 2016

Congress urged to “act immediately” to enact national program

Washington, D.C. (June 23, 2016) – Senate leaders announced today an agreement on legislative language aimed at establishing national standards for GMO food labeling and disclosure. 

“The Biotechnology Innovation Organization (BIO) welcomes the Senate’s carefully crafted, bipartisan legislative agreement to finally move our country forward on the GMO disclosure issue,” said Jim Greenwood, BIO’s President and CEO. “We commend Senate Agriculture Committee leadership for making the issue a priority in this Congressional session.”

BIO urges immediate action towards moving the bill forward.

“It is essential that the Congress – both the Senate and the House – act immediately to pass the Roberts-Stabenow agreement and send it to the President for his signature. Vermont’s mandatory GMO food labeling law goes into effect on July 1, and it is already generating chaos in the marketplace.”

The Senate agreement will provide consumers with consistent and reliable information about bioengineered food.  At the same time, the agreement will protect against confusion created by a state-by-state patchwork of requirements and avoid stigmatizing GMO technology, which has been repeatedly proven to be as safe as traditional food technologies.

“The time for Congressional action is now. Our government leaders must capture this moment to resolve the GMO labeling issue at a national level once and for all,” urged Greenwood. “The American food system and consumers will be better off for it.”

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…